EP
ENTA icon

Essential Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Essential Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.54K Sell
380
-1,136
-75% -$15.3K ﹤0.01% 1500
2026
Q1 		$19.1K Hold
1,516
– – 0.01% 949
2025
Q4 		$23.9K Hold
1,516
– – 0.01% 842
2025
Q3 		$18.1K Sell
1,516
-57
-4% -$455 0.01% 924
2025
Q2 		$11.9K Buy
+1,573
New +$9.46K ﹤0.01% 800

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's ENTA Position: Q2 2026 in Review

Essential Partners reduced its Enanta Pharmaceuticals (ENTA) stake by 75% in Q2 2026, selling an estimated $15.3K and leaving 380 shares worth $5.54K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Essential Partners first reported a position in ENTA in Q2 2025 and has held it in 5 quarters since. The position peaked at $23.9K in Q4 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Essential Partners held 380 shares of Enanta Pharmaceuticals worth $5.54K as of Q2 2026.
  • Essential Partners sold 1,136 Enanta Pharmaceuticals shares in Q2 2026, an estimated $15.3K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1500 holding.
  • Essential Partners first reported a position in Enanta Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Enanta Pharmaceuticals position peaked at $23.9K in Q4 2025.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.